Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts

Recruiting now

Conditions studied: Pancreatic Carcinoma

In brief

This study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier time when they might be more easily treated and cured.

Key facts

Study ID

NCT06271291

Run by

Mayo Clinic

People needed

30000

Starts

2024-12-12

Expected to finish

2029-11-01

Last updated by the study team

2026-06-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• PDAC FAMILY HISTORY OR PDAC RELATED GENETIC MUTATIONS:
• Age: 50 or older, plus at least one of the following:
• Mutation unknown or absent:
• 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject;
• OR 2+ affected first degree relatives [(FDR), defined as blood related parents, siblings, or children]
• Known pathogenic/likely pathogenic (P/LP) mutation in at least one of the following:
• CDKN2A/p16, Peutz-Jeghers syndrome (PJS) serine/threonine kinase 11 (STK11), Hereditary pancreatitis with confirmed protease serine 1 (PRSS1)
• OR 1+ or second degree relative (SDR) with PDAC and a known P/LP mutation in one or more of:
• ATM, BRCA1, BRCA2, PALB2, Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM), TP53
• HIGH-RISK OR WORRISOME PANCREATIC CYSTS:
• 18 years of age or greater and meeting Fukuoka worrisome (FW) or Fukuoka high-risk (FHR) criteria
• High risk stigmata:
• Obstructive Jaundice in a patient with cystic lesion of the head of the pancreas
• Enhancing mural nodule ≥ 5 mm
• Main pancreatic duct ≥ 10 mm
• Worrisome features:
• Presence of pancreatic duct stricture, defined as focal pancreatic duct narrowing with upstream duct => 6 mm
• Cyst ≥ 3 cm
• Enhancing mural nodule < 5 mm
• Thickened/Enhancing cyst wall
• Main duct size 5-9 mm
• Pancreatitis
• Lymphadenopathy
• Increased CA 19-9
• Cyst growth rate ≥ 5 mm /2 years

You may not qualify if…

• Is unable to provide informed consent
• Has received a non-autologous bone marrow transplant or has an active hematologic malignancy (i.e., leukemia or lymphoma)
• Current or prior history of PDAC or total pancreatectomy
• Is currently a prison inmate
• Is not able to speak or read English

Where it is running

• University of Pittsburgh — Pittsburgh, Pennsylvania, United States (enrolling)
• Piedmont Healthcare — Atlanta, Georgia, United States (enrolling)
• OSF Saint Francis Medical Center — Peoria, Illinois, United States (enrolling)
• The Johns Hopkins University School of Medicine — Baltimore, Maryland, United States (enrolling)
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
• Mayo Clinic in Rochester — Rochester, Minnesota, United States (enrolling)
• University of Nebraska Medical Center — Omaha, Nebraska, United States (enrolling)
• Oregon Health & Science University — Portland, Oregon, United States (enrolling)
• HonorHealth Research Institute — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.